BioMarin Pharmaceutical Inc. Website

BioMarin Pharmaceutical Inc.

NasdaqGS-BMRN

Company Overview

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

  • Name

    BioMarin Pharmaceutical Inc.

  • CEO

    Alexander Hardy

  • Website

    www.biomarin.com

  • Sector

    Biotechnology

  • Year Founded

    1996

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • BioMarin's approved drugs have been granted orphan-drug status in the US and the EU, providing them with at least seven and 10 years of market exclusivity, respectively.

  • BioMarin's drugs target rare chronic conditions that often require treatment from a very young age, and while locating eligible patients on a global level is challenging, the firm has high patient retention rates.

  • With a growing portfolio in an attractive rare-disease niche and an acceleration of profit growth since 2022, BioMarin could be an acquisition target for pharmaceutical firms with pipelines to fill.

Bears Say

  • Diagnosis of rare genetic diseases can be difficult, and BioMarin could have a hard time locating enough patients to recoup development and manufacturing costs.

  • BioMarin's gene therapy pipeline has faced setbacks, including a three-year delay in the US approval of Roctavian and the stalled development of PKU gene therapy BMN 307, as the Food and Drug Administration halted a trial to investigate potential cancer risks.

  • Viral contamination forced Genzyme to halt manufacturing of its enzyme replacement therapies in 2009, highlighting the manufacturing risk in the industry.

Source: Morningstar Analysis - Oct 29, 2025

What's happening

Nov 4, 2025 - Dec 4, 2025

BioMarin Pharmaceutical Inc. Shows Resilience Amid Mixed Investor Sentiment

  • BioMarin's stock rose by 2.0% over the past month, outperforming the S&P 500's decline of -0.3%.
  • The company experienced a significant boost following its announcement to present at the Jefferies Global Healthcare Conference, generating positive investor sentiment.
  • Analyst downgrades and mixed market perceptions highlight ongoing challenges despite steady revenue growth and regulatory achievements.

Over the past month, BioMarin Pharmaceutical Inc. (BMRN) recorded a positive stock movement of 2.0%, contrasting with the S&P 500's return of -0.3%. This performance reflects notable developments within the company amid mixed investor sentiment regarding its future in healthcare.

On November 11, BMRN experienced a substantial increase of 4.1% after announcing its participation in the Jefferies Global Healthcare Conference scheduled for November 18. Investors were optimistic about potential insights into BioMarin’s innovative therapies targeting rare genetic conditions, which are vital for maintaining interest in its strong pipeline amidst competitive pressures.

Earlier in November, on November 5, BMRN gained an additional 1.3% due to speculation surrounding possible acquisition strategies involving Jazz Pharmaceuticals and an analyst upgrade that raised earnings per share forecasts for next year to $5.78. These factors positively influenced market perceptions about BioMarin’s strategic positioning and growth opportunities within therapeutic areas.

However, this optimism faced headwinds when Bernstein analyst William Pickering lowered his price target from $95 to $88 while keeping an Outperform rating on November 3 due to concerns over future performance expectations for BMRN. Additionally, reports indicated mixed sentiments among analysts regarding BioMarin’s growth potential; recent downgrades reflected caution stemming from competition and pricing pressures impacting revenue projections.

Despite reporting steady revenue growth for Q3 and raising full-year guidance alongside key regulatory milestones like FDA acceptance for PALYNZIQ, investor caution remained prevalent due to perceived challenges ahead in navigating evolving market dynamics overall; while BMRN achieved a positive return relative to broader market trends at +2%, it underperformed compared to both the Health Care sector (XLV), which declined by -5.4%.

NasdaqGS:BMRN